p21 antibody

Catalog No. ABIN6252752

Product Details anti-p21 Antibody

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This p21 antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Specificity: Does not react with mouse and rat

Purification: Protein G affinity chromatography

Immunogen: Human recombinant protein was used as the immunogen for the p21 antibody.

Clone: DCS-60-2

Isotype: IgG2a kappa

Application Details

Application Notes: Flow Cytometry: 0.5-1 μg/million cells in 0.1ml

Immunofluorescence: 1-2 μg/mL

Western Blot: 1-2 μg/mL

Immunohistochemistry (FFPE): 2-4 μg/mL for 30 min at RT (1)

Prediluted format : incubate for 30 min at RT (2)

Optimal dilution of the p21 antibody to be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: PBS with 0.1 mg/mL BSA and 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot and Store at -20C. Avoid freez-thaw cycles.

Target Details for p21

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Alternative Name: p21 (CDKN1A Products)

Synonyms: CCND1 antibody, CDKN1A antibody, CAP20 antibody, CDKN1 antibody, CIP1 antibody, MDA-6 antibody, P21 antibody, SDI1 antibody, WAF1 antibody, p21CIP1 antibody, CDKI antibody, Cdkn1 antibody, Waf1 antibody, mda6 antibody, p21Cip1 antibody, p21WAF antibody, Cip1 antibody, UV96 antibody, p21 antibody, cip1 antibody, p16Xic2 antibody, sdi1 antibody, waf1 antibody, cap20 antibody, cdkn1 antibody, mda-6 antibody, p21cip1 antibody, si:ch1073-48m5.2 antibody, KRAS2 antibody, p21ras antibody, cyclin D1 antibody, cyclin dependent kinase inhibitor 1A antibody, cyclin-dependent kinase inhibitor 1A (P21) antibody, cyclin-dependent kinase inhibitor 1A antibody, cyclin-dependent kinase inhibitor 1A L homeolog antibody, cyclin-dependent kinase inhibitor 1 antibody, KRAS proto-oncogene, GTPase antibody, CCND1 antibody, CDKN1A antibody, Cdkn1a antibody, cdkn1a.L antibody, cki1 antibody, cdkn1a antibody, KRAS antibody

Background: This mAb recognizes a 21  kDa protein, identified as the p21WAF1 tumor suppressor protein. This mAb is highly specific to p21 and shows no cross-reaction with other closely related mitotic inhibitors. p21WAF1 is a specific inhibitor of cdk s and a tumor suppressor involved in the pathogenesis of a variety of malignancies. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Its expression is induced by the wild type, but not mutant, p53 suppressor protein. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).

Gene ID: 1026

UniProt: P38936

Pathways: p53 Signaling, PI3K-Akt Signaling, Cell Division Cycle, AMPK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagy